Corcept Therapeutics, Inc. is a commercial-stage pharmaceutical company, which engages in the business of discovering and developing pharmaceutical products and medications to treat severe ...

The M350 and the M500 are each updated versions of the Malibu Mirage and Malibu Meridian, respectively. The M700 is a derivative of Piper's M600 model, which itself was developed from the M500. The ...

In a pre-trial hearing Tuesday, April 8, Judge Jeanmarie Carroll denied bail to Rivaldo Jean, 23, and Imani Angela Cort, 21, who were accused of robbing and killing 54-year-old Frantzy Jeanty ...

Corcept Therapeutics Incorporated’s current stock price and volume Why Corcept Therapeutics Incorporated’s stock price changed recently Upgrades and downgrades for CORT from analysts CORT’s stock ...

Find more McKnight’s Pinnacle Awards content at this page. As a resident-aide caregiver with almost a quarter-century of dedicated service, Shirley Cort has set the highest standard of caregiving and ...

Corcept Therapeutics (CORT) stock shot up over 100% yesterday as markets reacted to the company’s announcement of promising outcomes from its Phase 3 ROSELLA trial, which assessed the efficacy ...

Shares of Corcept Therapeutics Incorporated CORT were up a staggering 109.1% on March 31 after the company announced data from the phase III ROSELLA study, which evaluated its pipeline candidate ...

Corcept Therapeutics Incorporated (NASDAQ:CORT) just the other day announced that it had achieved the primary endpoint of its pivotal phase 3 ROSELLA study. This late-stage study tested the ...

or the purchase of call options or similar derivatives in CORT over the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other ...

In this article, we are going to take a look at where Corcept Therapeutics Incorporated (NASDAQ:CORT) stands against other firms that kicked off the trading week stronger. The stock market began ...

Shares of biopharma company Corcept Therapeutics (NASDAQ:CORT) jumped 94.9% in the afternoon session after the company announced that its Phase 3 trial (ROSELLA) met its goal of improving ...